Summary & Overview
HCPCS J9263: Injection, Oxaliplatin 0.5 mg
HCPCS Level II code J9263 denotes an injectable chemotherapeutic agent: oxaliplatin, billed per 0.5 mg unit. As a widely used cytotoxic drug in colorectal and other cancer regimens, accurate billing of oxaliplatin units is important for clinical documentation, reimbursement, and inventory control across infusion centers and outpatient hospital clinics. Nationally, consistent coding of drug units affects payment accuracy and claims processing for both commercial insurers and government payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9263 represents, typical sites of service, and the clinical context for oxaliplatin use. The publication summarizes benchmarking concepts related to unit-based drug billing, common modifier conventions (listed separately), and payer coverage patterns where available.
This summary provides guidance on where J9263 fits within chemotherapy service lines, the operational implications for infusion centers and outpatient clinics, and what to expect in payer review processes. Data not available in the input is clearly noted in relevant sections.
Billing Code Overview
HCPCS Level II code J9263 represents an injection of oxaliplatin, 0.5 mg. This code denotes a chemotherapeutic drug preparation and administration charge for oxaliplatin measured in 0.5 mg units.
-
Service type: Drug administration / chemotherapy drug supply
-
Typical site of service: Infusion center or outpatient hospital clinic where intravenous chemotherapy is administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A patient with stage III colon adenocarcinoma presents to the outpatient oncology infusion suite for adjuvant chemotherapy. The oncology team prescribes an oxaliplatin-containing regimen (for example, FOLFOX) administered intravenously as part of a multi‑agent infusion. The chemotherapy nurse confirms pre‑treatment consent, verifies baseline labs (CBC, CMP), assesses neuropathy and performance status, and obtains vital signs. Oxaliplatin is compounded by pharmacy into the appropriate concentration and dose (billed per 0.5 mg unit as J9263) and delivered to the infusion chair. The nurse administers oxaliplatin via peripheral IV or implanted port over the protocol‑specified infusion time while monitoring for hypersensitivity, acute cold‑induced neuropathy, and infusion reactions. Supportive medications (antiemetic prophylaxis, IV fluids) are given before or during the visit; observation continues post‑infusion for adverse effects. Documentation includes chemotherapy order, lot numbers, dose calculation, infusion start/stop times, patient tolerance, and any modifier‑relevant events (e.g., discontinued infusion, split/shared services). Typical site of service is an outpatient hospital infusion center, physician office infusion suite, or ambulatory infusion clinic.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifiers used | Standard billing when no special circumstances apply |